While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Speaking to Xinhua, Guenter said China is a country of great importance and enormous potential for the company, and expressed confidence that Merck will invest more in China in the future.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $123 from $130 and keeps an Equal Weight rating on the shares. The Q3 reported highlighted ongoing uncertainty ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Oct 31 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories ...

(Reuters) -Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S.